Boston Partners Has $27.93 Million Stock Position in Catalyst Pharmaceuticals, Inc. $CPRX

Boston Partners raised its stake in Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX) by 0.6% in the 2nd quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 1,282,722 shares of the biopharmaceutical company’s stock after purchasing an additional 7,397 shares during the period. Boston Partners owned 1.05% of Catalyst Pharmaceuticals worth $27,928,000 as of its most recent SEC filing.

A number of other hedge funds have also recently added to or reduced their stakes in the company. Algert Global LLC increased its holdings in shares of Catalyst Pharmaceuticals by 1.0% during the first quarter. Algert Global LLC now owns 48,390 shares of the biopharmaceutical company’s stock valued at $1,173,000 after acquiring an additional 470 shares in the last quarter. Mission Wealth Management LP grew its position in Catalyst Pharmaceuticals by 5.0% in the 2nd quarter. Mission Wealth Management LP now owns 10,620 shares of the biopharmaceutical company’s stock valued at $230,000 after purchasing an additional 510 shares during the period. Hancock Whitney Corp increased its stake in Catalyst Pharmaceuticals by 1.4% during the 1st quarter. Hancock Whitney Corp now owns 38,847 shares of the biopharmaceutical company’s stock valued at $942,000 after purchasing an additional 525 shares in the last quarter. New York State Teachers Retirement System increased its stake in Catalyst Pharmaceuticals by 0.4% during the 2nd quarter. New York State Teachers Retirement System now owns 149,887 shares of the biopharmaceutical company’s stock valued at $3,253,000 after purchasing an additional 577 shares in the last quarter. Finally, Amalgamated Bank raised its holdings in Catalyst Pharmaceuticals by 2.0% during the second quarter. Amalgamated Bank now owns 32,619 shares of the biopharmaceutical company’s stock worth $708,000 after buying an additional 654 shares during the last quarter. Institutional investors and hedge funds own 79.22% of the company’s stock.

Analyst Ratings Changes

A number of research analysts have recently issued reports on CPRX shares. Weiss Ratings reiterated a “hold (c+)” rating on shares of Catalyst Pharmaceuticals in a report on Wednesday, October 8th. Oppenheimer reaffirmed an “outperform” rating and issued a $33.00 price target on shares of Catalyst Pharmaceuticals in a research report on Friday, November 7th. Zacks Research downgraded Catalyst Pharmaceuticals from a “strong-buy” rating to a “hold” rating in a research note on Tuesday, August 19th. Wall Street Zen raised shares of Catalyst Pharmaceuticals from a “hold” rating to a “buy” rating in a report on Sunday, November 16th. Finally, Citigroup upped their target price on Catalyst Pharmaceuticals from $31.00 to $33.00 and gave the company a “buy” rating in a report on Friday, November 7th. Two analysts have rated the stock with a Strong Buy rating, six have assigned a Buy rating and two have issued a Hold rating to the company. Based on data from MarketBeat, the stock currently has an average rating of “Buy” and an average target price of $32.67.

Catalyst Pharmaceuticals Price Performance

Shares of CPRX opened at $23.43 on Friday. Catalyst Pharmaceuticals, Inc. has a 1 year low of $19.05 and a 1 year high of $26.58. The stock’s fifty day moving average price is $21.30 and its two-hundred day moving average price is $21.73. The firm has a market cap of $2.88 billion, a PE ratio of 14.20, a PEG ratio of 0.84 and a beta of 0.79.

Catalyst Pharmaceuticals (NASDAQ:CPRX) last posted its earnings results on Monday, September 25th. The biopharmaceutical company reported $0.28 earnings per share (EPS) for the quarter. Catalyst Pharmaceuticals had a return on equity of 40.78% and a net margin of 37.36%.The firm had revenue of $53.11 million for the quarter. Sell-side analysts anticipate that Catalyst Pharmaceuticals, Inc. will post 1.9 earnings per share for the current fiscal year.

Catalyst Pharmaceuticals announced that its board has authorized a share buyback plan on Wednesday, October 1st that permits the company to buyback $200.00 million in outstanding shares. This buyback authorization permits the biopharmaceutical company to reacquire up to 8.3% of its stock through open market purchases. Stock buyback plans are typically a sign that the company’s leadership believes its stock is undervalued.

Insider Transactions at Catalyst Pharmaceuticals

In related news, insider Brian Elsbernd sold 30,000 shares of the business’s stock in a transaction dated Monday, September 8th. The stock was sold at an average price of $20.30, for a total transaction of $609,000.00. Following the completion of the transaction, the insider directly owned 271,039 shares in the company, valued at $5,502,091.70. The trade was a 9.97% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Insiders sold a total of 80,000 shares of company stock worth $1,596,200 over the last three months. 10.40% of the stock is currently owned by company insiders.

About Catalyst Pharmaceuticals

Catalyst Pharmaceuticals, Inc, a commercial-stage biopharmaceutical company, focuses on developing and commercializing therapies for people with rare debilitating, chronic neuromuscular, and neurological diseases in the United States. It offers Firdapse, an amifampridine phosphate tablets for the treatment of patients with lambert-eaton myasthenic syndrome (LEMS); and Ruzurgi for the treatment of pediatric LEMS patients.